The goal in this study was to generate differing levels of FSHD-like severity using our FLExD mouse model and characterize the progression of pathology in ways useful to those performing preclinical testing of candidate DUX4-targeted therapeutics. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.